{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:42:41Z","timestamp":1785526961041,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Aromatase inhibitors (AIs) are standard therapy for postmenopausal women with hormone receptor-positive breast cancer. However, prolonged AI use is associated with increased cardiovascular (CV) risk, including hypertension, and endothelial dysfunction. This study evaluated the longitudinal changes in endothelial function during AI therapy, and whether AI-induced endothelial dysfunction is reversible post-discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were recruited before or within one month of AI initiation (Pre\/early AI), during AI therapy, and after discontinuation (Post-AI) from two prospective studies. Patients with hypertension, hyperlipidemia, diabetes, or tobacco use were excluded. Vascular assessments included peripheral arterial tonometry (EndoPAT) for endothelial function (abnormal if ratio\u2009&lt;\u20091.67) and artery elasticity indices. Estradiol, lipid profiles, and inflammatory markers were also measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 12 Pre\/early AI patients, 67 visits from 41 patients during AI (median 2.89\u2009years on AI), and 9 Post-AI patients (median 4.17\u2009years follow-up). EndoPAT ratio was significantly impaired during AI therapy compared to the Pre\/early AI (median: 0.86 vs 2.19). The EndoPAT ratio declined as early as six months and showed a progressive decline over time. Post-discontinuation, the EndoPAT ratio was only partially and not significantly restored (median: 1.08) despite full estradiol restoration and long follow-up. Arterial elasticity showed no significant changes. Systolic blood pressure increased modestly during AI therapy and returned to baseline after discontinuation, while diastolic pressure remained unchanged. Circulating interleukin-6 and tumor necrosis factor-\u03b1 significantly decreased following AI discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AI therapy is associated with significant and progressive endothelial dysfunction, which does not fully recover after treatment cessation, highlighting the importance of CV monitoring in patients receiving long-term AI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-08007-2","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:24:29Z","timestamp":1782127469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?"],"prefix":"10.1007","volume":"217","author":[{"given":"Mohamed S.","family":"Dabour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Duprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beshay N.","family":"Zordoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5433-4810","authenticated-orcid":false,"given":"Anne H.","family":"Blaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"1","key":"8007_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"8007_CR2","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.3390\/cancers15164190","volume":"15","author":"I Bekes","year":"2023","unstructured":"Bekes I, Huober J (2023) Extended Adjuvant endocrine therapy in early breast cancer patients\u2014review and perspectives. Cancers (Basel) 15(16):4190. https:\/\/doi.org\/10.3390\/cancers15164190","journal-title":"Cancers (Basel)"},{"issue":"1","key":"8007_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jnci\/djx141","volume":"110","author":"H Goldvaser","year":"2018","unstructured":"Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocana A, Ribnikar D, Amir E (2018) Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 110(1):31\u201339. https:\/\/doi.org\/10.1093\/jnci\/djx141","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"8007_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","volume":"17","author":"J Foglietta","year":"2017","unstructured":"Foglietta J, Inno A, de Iuliis F, Sini V, Duranti S, Turazza M, Tarantini L, Gori S (2017) Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin Breast Cancer 17(1):11\u201317. https:\/\/doi.org\/10.1016\/j.clbc.2016.07.003","journal-title":"Clin Breast Cancer"},{"key":"8007_CR5","doi-asserted-by":"publisher","unstructured":"SenthilKumar G, Katunaric B, Bordas-Murphy H, Sarvaideo J, Freed JK (2023) Estrogen and the vascular endothelium: the unanswered questions. Endocrinology 164(6). https:\/\/doi.org\/10.1210\/endocr\/bqad079","DOI":"10.1210\/endocr\/bqad079"},{"issue":"1","key":"8007_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12944-019-1175-4","volume":"18","author":"C Wang","year":"2019","unstructured":"Wang C, Niimi M, Kitajima S, Matsuhisa F, Yan H, Dong S, Liang J, Fan J (2019) Sex hormones affect endothelial lipase-mediated lipid metabolism and atherosclerosis. Lipids Health Dis 18(1):226. https:\/\/doi.org\/10.1186\/s12944-019-1175-4","journal-title":"Lipids Health Dis"},{"issue":"1","key":"8007_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40959-024-00227-z","volume":"10","author":"A Shaaban","year":"2024","unstructured":"Shaaban A, Petersen A, Beckwith H, Florea N, Potter DA, Yee D, Vogel RI, Duprez D, Blaes AH (2024) Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time. Cardio-Oncology 10(1):27. https:\/\/doi.org\/10.1186\/s40959-024-00227-z","journal-title":"Cardio-Oncology"},{"key":"8007_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/VHRM.S151847","volume":"14","author":"AH Blaes","year":"2018","unstructured":"Blaes AH, Mulrooney DA, Vogel RI, Solovey A, Hebbel R, Peterson BA, Neglia JP, Biewen C, Konety SH, Duprez DA (2018) Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study. Vasc Health Risk Manag 14:205\u2013211. https:\/\/doi.org\/10.2147\/VHRM.S151847","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"8007_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-017-4447-6","volume":"166","author":"A Blaes","year":"2017","unstructured":"Blaes A, Beckwith H, Florea N, Hebbel R, Solovey A, Potter D, Yee D, Vogel R, Luepker R, Duprez D (2017) Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Res Treat 166(2):541\u2013547. https:\/\/doi.org\/10.1007\/s10549-017-4447-6","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"8007_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/aje\/kwr120","volume":"174","author":"DA Duprez","year":"2011","unstructured":"Duprez DA, Jacobs DR Jr, Lutsey PL, Bluemke DA, Brumback LC, Polak JF, Peralta CA, Greenland P, Kronmal RA (2011) Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis. Am J Epidemiol 174(5):528\u2013536. https:\/\/doi.org\/10.1093\/aje\/kwr120","journal-title":"Am J Epidemiol"},{"issue":"2","key":"8007_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.21037\/gs.2018.02.03","volume":"7","author":"IA Woelfel","year":"2018","unstructured":"Woelfel IA, Fernandez LJ, Idowu MO, Takabe K (2018) A high burden of comorbid conditions leads to decreased survival in breast cancer. Gland Surg 7(2):216\u2013227. https:\/\/doi.org\/10.21037\/gs.2018.02.03","journal-title":"Gland Surg"},{"key":"8007_CR12","doi-asserted-by":"publisher","unstructured":"Lee JA, Pakpahan R, Amante DJ, Gerber BS, Yang L (2025) Comorbidity prevalence and incidence in cancer survivors: a longitudinal all of us study. JNCI Cancer Spectr 9(6):kaf093. https:\/\/doi.org\/10.1093\/jncics\/pkaf093","DOI":"10.1093\/jncics\/pkaf093"},{"issue":"6","key":"8007_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL (2024) Breast cancer statistics 2024. CA Cancer J Clin 74(6):477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"8007_CR14","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1","DOI":"10.1016\/S0140-6736(15)61074-1"},{"issue":"7","key":"8007_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","volume":"141","author":"F Khosrow-Khavar","year":"2020","unstructured":"Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L (2020) Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation 141(7):549\u2013559. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044750","journal-title":"Circulation"},{"key":"8007_CR16","doi-asserted-by":"publisher","unstructured":"Berbari E, Anees A, Kaur R, Ayeni FE, Edirimanne S (2025) The risk of cardiovascular disease following aromatase inhibitor therapy for breast cancer in postmenopausal women: a systematic review and meta-analysis. Breast Care (Basel) 1\u201322. https:\/\/doi.org\/10.1159\/000546089","DOI":"10.1159\/000546089"},{"issue":"1","key":"8007_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","volume":"27","author":"PT Bradshaw","year":"2016","unstructured":"Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD (2016) Cardiovascular disease mortality among breast cancer survivors. Epidemiology 27(1):6\u201313. https:\/\/doi.org\/10.1097\/EDE.0000000000000394","journal-title":"Epidemiology"},{"issue":"5","key":"8007_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM (2018) Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol 34(5):575\u2013584. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.005","journal-title":"Can J Cardiol"},{"issue":"2","key":"8007_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.31083\/j.rcm2302073","volume":"23","author":"J Zhang","year":"2022","unstructured":"Zhang J (2022) Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med 23(2):73. https:\/\/doi.org\/10.31083\/j.rcm2302073","journal-title":"Rev Cardiovasc Med"},{"issue":"5","key":"8007_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.118.11554","volume":"72","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, Kario K, Sugiyama S, Munakata M, Ito H, Ueda S, Vlachopoulos C, Higashi Y, Inoue T, Node K (2018) Physiological diagnostic criteria for vascular failure. Hypertension 72(5):1060\u20131071. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11554","journal-title":"Hypertension"},{"issue":"16","key":"8007_CR21","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/eurjpc\/zwad225","volume":"30","author":"N Rajai","year":"2023","unstructured":"Rajai N, Toya T, Sara JD, Rajotia A, Lopez-Jimenez F, Lerman LO, Lerman A (2023) Prognostic value of peripheral endothelial function on major adverse cardiovascular events above traditional risk factors. Eur J Prev Cardiol 30(16):1781\u20131788. https:\/\/doi.org\/10.1093\/eurjpc\/zwad225","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"8007_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/MCA.0000000000000666","volume":"29","author":"R Maor","year":"2018","unstructured":"Maor R, Sara JDS, Wanous AA, Maor E, Pruthi S, Lerman A, Sandhu NP (2018) Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer. Coron Artery Dis 29(8):687\u2013693. https:\/\/doi.org\/10.1097\/MCA.0000000000000666","journal-title":"Coron Artery Dis"},{"key":"8007_CR23","doi-asserted-by":"publisher","first-page":"727380","DOI":"10.3389\/fragi.2021.727380","volume":"2","author":"M Davezac","year":"2021","unstructured":"Davezac M, Buscato M, Zahreddine R, Lacolley P, Henrion D, Lenfant F, Arnal JF, Fontaine C (2021) Estrogen receptor and vascular aging. Front Aging 2:727380. https:\/\/doi.org\/10.3389\/fragi.2021.727380","journal-title":"Front Aging"},{"issue":"4","key":"8007_CR24","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/HYPERTENSIONAHA.107.106807","volume":"51","author":"C Pinna","year":"2008","unstructured":"Pinna C, Cignarella A, Sanvito P, Pelosi V, Bolego C (2008) Prolonged ovarian hormone deprivation impairs the protective vascular actions of estrogen receptor \u03b1 agonists. Hypertension 51(4):1210\u20131217. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.106807","journal-title":"Hypertension"},{"issue":"3","key":"8007_CR25","doi-asserted-by":"publisher","first-page":"F349","DOI":"10.1152\/ajprenal.00055.2022","volume":"323","author":"RN Almutlaq","year":"2022","unstructured":"Almutlaq RN, Newell-Fugate AE, Evans LC, Fatima H, Gohar EY (2022) Aromatase inhibition increases blood pressure and markers of renal injury in female rats. Am J Physiol Renal Physiol 323(3):F349\u2013F360. https:\/\/doi.org\/10.1152\/ajprenal.00055.2022","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"8007_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/curroncol32060344","volume":"32","author":"JA De La Cruz-Vargas","year":"2025","unstructured":"De La Cruz-Vargas JA, Gomez H, Talavera JE, Gonzales-Rospigliosi C, Cordova Salazar AA, Pichardo-Rodriguez R (2025) Prognostic relevance of inflammatory cytokines Il-6 and TNF-alpha in patients with breast cancer: a systematic review and meta-analysis. Curr Oncol 32(6):344. https:\/\/doi.org\/10.3390\/curroncol32060344","journal-title":"Curr Oncol"},{"key":"8007_CR27","doi-asserted-by":"publisher","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143(21):e984\u2013e1010. https:\/\/doi.org\/10.1161\/CIR.0000000000000973","DOI":"10.1161\/CIR.0000000000000973"},{"key":"8007_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijcard.2015.03.118","volume":"185","author":"RH Olsen","year":"2015","unstructured":"Olsen RH, Pedersen LR, Jurs A, Snoer M, Haugaard SB, Prescott E (2015) A randomised trial comparing the effect of exercise training and weight loss on microvascular function in coronary artery disease. Int J Cardiol 185:229\u2013235. https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.118","journal-title":"Int J Cardiol"},{"issue":"1","key":"8007_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11695-012-0729-6","volume":"23","author":"J Merino","year":"2013","unstructured":"Merino J, Megias-Rangil I, Ferre R, Plana N, Girona J, Rabasa A, Aragones G, Cabre A, Bonada A, Heras M, Masana L (2013) Body weight loss by very-low-calorie diet program improves small artery reactive hyperemia in severely obese patients. OBES Surg 23(1):17\u201323. https:\/\/doi.org\/10.1007\/s11695-012-0729-6","journal-title":"OBES Surg"},{"issue":"6","key":"8007_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/jcsm.12340","volume":"9","author":"JI Yoo","year":"2018","unstructured":"Yoo JI, Kim MJ, Na JB, Chun YH, Park YJ, Park Y, Hah YS, Ha YC, Park KS (2018) Relationship between endothelial function and skeletal muscle strength in community dwelling elderly women. J Cachexia Sarcopenia Muscle 9(6):1034\u20131041. https:\/\/doi.org\/10.1002\/jcsm.12340","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08007-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:07:13Z","timestamp":1785521233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08007-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8007"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08007-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Both studies were approved by the University of Minnesota Institutional Review Board and Cancer Center Review Committee, and all patients provided written informed consent according to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}